Yayınlar & Eserler

Yayın Ağı
Makaleler 30
Tümü (30)
SCI-E, SSCI, AHCI (20)
SCI-E, SSCI, AHCI, ESCI (23)
ESCI (3)
Scopus (26)
TRDizin (12)

1. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

Kalem A., Kus T., Sahin T. K., DİZDAR Ö., Efil S. C., Sendur M. A. N., et al.
Cancers , cilt.17, sa.17, 2025 (SCI-Expanded) identifier identifier

2. Association of TILs and HER2-low status with pathological response in triple-negative breast cancer

Deliktaş Onur İ., Kurukafa D., AĞYOL Y., Firat H. G., Sertesen Çamöz E., Türkel A., et al.
Medicine (United States) , cilt.104, sa.33, 2025 (SCI-Expanded) identifier identifier

3. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

Kalem A., Kus T., Gokcek S., ÜNEK İ. T., Sahin T. K., DİZDAR Ö., et al.
Journal of Clinical Medicine , cilt.14, sa.16, 2025 (SCI-Expanded) identifier identifier

4. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.
Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded) identifier identifier

5. Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi

kahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.
Turkish Journal of Clinics and Laboratory , cilt.16, sa.2, ss.255-262, 2025 (Hakemli Dergi) identifier

6. Clinicopathological Features and Survival Outcomes of Colorectal Cancer Patients Under 40 Years: A 20-Years Single-Center Experience

Kaan A., Demircan N. C., ÖZGÜR S. Ş., AKYOL T. B., majıdova n., Kocaaslan E., et al.
Uluslararası Hematoloji-Onkoloji Dergisi , cilt.35, sa.2, ss.104-111, 2025 (SCI-Expanded, Scopus, TRDizin) identifier

7. Metastatik Kolorektal Kanser Tedavisinde Regorafenib Etkinliğini Etkileyen Prognostik Faktörler

SEVER N., bayoglu i. v.
Namık Kemal Tıp Dergisi , cilt.13, sa.2, ss.170-177, 2025 (Hakemli Dergi) identifier

8. Evaluation of Pancreatic Atrophy in Patients with Hepatocellular Carcinoma Receiving Sorafenib Treatment

Kaan A., Zengin G., majıdova n., SEVER N., Ergelen R., Köstek O., et al.
Eurasian Journal of Medical Investigation , cilt.9, sa.1, ss.29-35, 2025 (Hakemli Dergi) identifier

9. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors

Guliyev M., Güren A. K., Özge E., Çolak R., Majidova N., Alkan Şen G., et al.
Cancers , cilt.17, sa.4, 2025 (SCI-Expanded) identifier identifier

10. Lung Immune Prognostic Index (LIPI): Prognostic predictor for patients with extensive-stage small-cell lung cancer

Majidova N., Seyyar M., Guren A. K., Kocaaslan E., Kircali M. F., Sever N., et al.
Marmara Medical Journal , cilt.38, sa.1, ss.24-28, 2025 (ESCI) identifier

11. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis

SEVER N., Yıldırım S., Gurbuz A. F., Karakaş Kılıç D., Zeynelgil E., Altintaş Y. E., et al.
Medicina (Lithuania) , cilt.61, sa.1, 2025 (SCI-Expanded) identifier identifier

12. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

Sekmek S., Ozsan Çelebi S. N., Bayram D., Erol C., Kos F. T., Sendur M. A. N., et al.
Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded) Creative Commons License identifier identifier

13. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group

AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., Ahmed M., et al.
International Journal of Gynecological Cancer , cilt.34, sa.9, ss.1359-1365, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

14. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: A case report

Güren A. K., KOCAASLAN E., AĞYOL Y., Majidova N., Sever N., EREL P., et al.
Anti-Cancer Drugs , cilt.35, sa.8, ss.769-773, 2024 (SCI-Expanded) identifier identifier

15. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study

Şenocak Taşçı E., Mutlu A. U., Saylık O., ÖLMEZ Ö. F., BİLİCİ A., Sünger E., et al.
Cancers , cilt.16, sa.18, 2024 (SCI-Expanded) identifier identifier

16. Evaluation of sarcopenia-associated survival in breast cancer with computed tomography-based pectoral muscle area measurements

KUZAN B. N., MAJIDOVA N., ILGIN C., ARSLAN H., KURŞUN M., ÖZGÜVEN S., et al.
MARMARA MEDICAL JOURNAL , cilt.37, sa.2, ss.178-184, 2024 (ESCI) Sürdürülebilir Kalkınma identifier

17. The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer

Ozkul O., Sahin E., Cabuk D., SEVER N., majıdova n., bayoglu i. v., et al.
Eurasian Journal of Medical Investigation , cilt.8, sa.1, ss.58-66, 2024 (Hakemli Dergi) Creative Commons License identifier

18. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

Akdağ G., Alan Ö., Doğan A., Yildirim S., Kinikoğlu O., Majidova N., et al.
Journal of Oncological Science , cilt.10, sa.2, ss.89-96, 2024 (Scopus) identifier

19. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

KÖSTEK O., DEMİREL A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.
Journal of Chemotherapy , cilt.36, sa.7, ss.613-621, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

20. Systemic Inflammation Response Index and Pan-Immune-Inflammation Value: Prognostic Significance in Metastatic Melanoma

Majidova N., Kircali M. F., Güren A. K., Sever N., KOCAASLAN E., AĞYOL Y., et al.
Journal of Oncological Science , cilt.10, sa.3, ss.144-149, 2024 (Scopus) identifier

21. Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience

Majidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.34, sa.1, ss.20-27, 2024 (SCI-Expanded, Scopus, TRDizin) identifier identifier

22. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

BAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., et al.
Journal of Clinical Medicine , cilt.12, sa.19, 2023 (SCI-Expanded) Creative Commons License identifier identifier

23. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

KAHRAMAN S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.
FUTURE ONCOLOGY , cilt.19, ss.727-736, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

24. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., et al.
BMC cancer , cilt.23, sa.1, ss.136, 2023 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

25. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib

ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., et al.
Journal of Oncological Science , cilt.9, sa.2, ss.53-61, 2023 (Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier

26. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.
BREAST , cilt.66, ss.85-88, 2022 (SCI-Expanded) Creative Commons License identifier identifier identifier

27. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma

AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., et al.
Nutrition and Cancer , cilt.74, sa.7, ss.2499-2507, 2022 (SCI-Expanded) identifier identifier identifier

28. Varicella-Zoster Virus Infection and Brivudine Therapy: Unexpected Response in Sarcoma Patient

KÖSTEK O., Sari M., BAYOĞLU İ. V.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.2, ss.182-185, 2022 (ESCI) identifier identifier identifier

29. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)

TANRIVERDİ Ö., Kaytan-Saglam E., Ulger S., Bayoglu İ. V., Turker I., Ozturk-Topcu T., et al.
MEDICAL ONCOLOGY , cilt.31, sa.9, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

30. Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial

Yildiz I., Ekenel M., Akman T., Kocar M., UYSAL M., Kanitez M., et al.
ANTICANCER RESEARCH , cilt.34, sa.8, ss.4329-4334, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Breast cancer subtypes and the risk of distant relapse after breast conserving surgery or mastectomy: An Anatolian Society of Medical Oncology study.

Kaplan M. A., Urakci Z., Uncu D., Dane F., Ozkan M., Akman T., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma identifier
Metrikler

Yayın

33

Yayın (WoS)

24

Yayın (Scopus)

26

Atıf (WoS)

29

H-İndeks (WoS)

2

Atıf (Scopus)

81

H-İndeks (Scopus)

4

Atıf (Scholar)

1

H-İndeks (Scholar)

1

Açık Erişim

7
BM Sürdürülebilir Kalkınma Amaçları